| Revision as of 17:51, 13 September 2011 editAnypodetos (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers39,350 editsm Stub sorting← Previous edit |
Latest revision as of 20:01, 20 December 2023 edit undoJJMC89 bot III (talk | contribs)Bots, Administrators3,687,180 editsm Moving Category:Pfizer brands to Category:Drugs developed by Pfizer per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands |
| (24 intermediate revisions by 15 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
| ⚫ |
| verifiedrevid = 450281305 |
|
|
|
| Watchedfields = changed |
|
⚫ |
| verifiedrevid = 464210715 |
|
| type = mab |
|
| type = mab |
|
| image = |
|
| image = |
| Line 13: |
Line 16: |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category= |
|
| pregnancy_category= |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
| Line 24: |
Line 27: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number = 1178862-65-1 |
|
| CAS_number = 1178862-65-1 |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
| Line 30: |
Line 34: |
|
| UNII = 1TG15H1XE9 |
|
| UNII = 1TG15H1XE9 |
|
| PubChem = |
|
| PubChem = |
|
|
| KEGG = D09952 |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
|
| ChemSpiderID = none |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
| C=6552 | H=10158 | N=1730 | O=2090 | S=52 |
|
| C=6552 | H=10158 | N=1730 | O=2090 | S=52 |
|
| molecular_weight = 148.3 kDa |
|
|
}} |
|
}} |
|
|
|
|
|
'''Ponezumab''' is a humanized monoclonal antibody designed for the treatment of ].<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab|publisher=]|url=http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf}}</ref> |
|
'''Ponezumab''' is a humanized monoclonal antibody designed for the treatment of ].<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab|publisher=]|url=http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf}}</ref><ref>{{cite book | vauthors = Popescu CD, Trofin D, Ignat B, Matei D | chapter = New Aspects of Therapeutic Management in Alzheimer`s Disease | veditors = Atta-ur-Rahman |title=Frontiers in Clinical Drug Research: Alzheimer Disorders | volume = 3 |date=2014 |publisher=Bentham Science Publishers |location=Sharjah |isbn=978-1-68108-068-0 | doi = 10.2174/9781681080680115030004 | page = 55 }}</ref> |
|
|
|
|
|
Ponezumab was developed by ] Inc. |
|
Ponezumab was developed by ] Inc. |
|
|
In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.<ref>{{cite web|title=Alzforum|url=http://www.alzforum.org/new/detail.asp?id=2950}}</ref> |
|
|
|
|
|
== References == |
|
== References == |
|
|
{{Reflist}} |
|
<references/> |
|
|
|
|
|
|
{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}} |
|
{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}} |
|
|
|
|
|
] |
|
] |
|
|
] |
|
|
|
|
|
] |
|
|
|
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |
|
{{nervous-system-drug-stub}} |
|
{{nervous-system-drug-stub}} |